Among FDA approved therapies sorafenib is known to be a FLT3 inhibitor and regorafenib also has weak anti-FLT3 activity.[33] At the time of referral to the CCTT the patient had metastatic disease to the liver and spleen. Here, FLT3 is linked to metastatic neoplasm.